Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   42585   clinical trials with a EudraCT protocol, of which   7011   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2022-000795-19
    Sponsor's Protocol Code Number:HIPRA-HH-10
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2022-03-11
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2022-000795-19
    A.3Full title of the trial
    A PHASE IIB, DOUBLE-BLIND, RANDOMIZED, ACTIVE CONTROLLED, MULTI-CENTER, NON-INFERIORITY TRIAL TO ASSESS IMMUNOGENICITY AND SAFETY OF A BOOSTER VACCINATION WITH A RECOMBINANT PROTEIN RBD FUSION DIMER CANDIDATE (PHH-1V) AGAINST SARS-COV-2, IN ADULTS FULLY VACCINATED WITH ADENOVIRUS VACCINE AGAINST COVID-19
    Ensayo clínico de no inferioridad de fase IIb, doble-ciego, aleatorizado, con control activo, multicéntrico, para evaluar la inmunogenicidad y seguridad de una vacuna candidata de refuerzo de proteína recombinante dimérica de fusión RBD (PHH-1V) contra el SARS-CoV-2, en adultos vacunados con pauta completa con vacunas de adenovirus contra el COVID-19.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    SAFETY OF A BOOSTER VACCINATION WITH A RECOMBINANT PROTEIN RBD FUSION DIMER CANDIDATE (PHH-1V) AGAINST SARS-COV-2, IN ADULTS FULLY VACCINATED WITH ADENOVIRUS VACCINE AGAINST COVID-19
    Seguridad e inmunogenicidad de una dosis de refuerzo de una vacuna candidata de proteína recombinante frente al COVID-19, en adultos vacunados con pauta completa con vacunas de adenovirus.
    A.4.1Sponsor's protocol code numberHIPRA-HH-10
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorHIPRA SCIENTIFIC
    B.1.3.4CountrySpain
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportHIPRA SCIENTIFIC S.L.U
    B.4.2CountrySpain
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationHIPRA SCIENTIFIC
    B.5.2Functional name of contact pointRegulatory Affairs HH Director
    B.5.3 Address:
    B.5.3.1Street AddressAvda. La Selva, 135
    B.5.3.2Town/ cityAmer
    B.5.3.3Post code17170
    B.5.3.4CountrySpain
    B.5.6E-mailteresa.prat@hipra.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namePHH-1V
    D.3.2Product code PHH-1V
    D.3.4Pharmaceutical form Emulsion for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntramuscular use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNSARS-CoV-2 virus, variants B.1.351-B.1.1.7, spike protein, receptor binding domain fusion heterodimer
    D.3.9.2Current sponsor codePHH-1V
    D.3.9.3Other descriptive namePHH-1V
    D.3.9.4EV Substance CodeSUB223972
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number40
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Comirnaty
    D.2.1.1.2Name of the Marketing Authorisation holderBioNTech Manufacturing GmbH
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Dispersion for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntramuscular use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTozinameran
    D.3.9.1CAS number -
    D.3.9.2Current sponsor code-
    D.3.9.3Other descriptive name-
    D.3.9.4EV Substance CodeSUB210693
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number30
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    SARS-COV-2
    SARS-COV-2
    E.1.1.1Medical condition in easily understood language
    COVID-19 infection
    Infección por COVID-19
    E.1.1.2Therapeutic area Diseases [C] - Virus Diseases [C02]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 23.0
    E.1.2Level LLT
    E.1.2Classification code 10084272
    E.1.2Term SARS-CoV-2 infection
    E.1.2System Organ Class 100000004862
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    1. To determine and compare the changes of the immunogenicity measured by pseudovirus neutralisation against Omicron strain at Baseline and Day 14, in subjects who have received two doses of Vaxzevria vaccine and PHH-1V as a booster, versus subjects who have received two doses of Vaxzevria and Comirnaty as a booster, at least 91 days and with a maximum of 365 days before day 0.
    2. To assess the safety and tolerability of PHH-1V as a booster dose in healthy adult subjects fully vaccinated against COVID-19 with the Vaxzevria vaccine.
    1. Determinar y comparar los cambios en la immunogenicidad medida mediante neutralización por pseudovirión contra la cepa Omicron en la visita basal y el día 14, en los sujetos que han recibido dos dosis de Vazxevria y PHH-1V como booster, versus aquellos sujetos que han recibido dos dosis de Vaxzevria y Comirnaty como booster, al menos 91 días y hasta 365 días antes del día 0.
    2. Evaluar la seguridad y tolerabilidad del booster de PHH-1V en adultos sanos vacunados con pauta completa de Vazxevria contra COVID-19.
    E.2.2Secondary objectives of the trial
    1. To determine and compare the changes of the immunogenicity (PBNA) against VOCs Beta and Delta, at Baseline and at Day 14, 98 and 182 in subjects of both arms.
    2. To determine and compare the changes of the immunogenicity measured by SARS-CoV-2 PBNA against Omicron at Day 98 and 182 in subjects of both arms.
    3. To determine and compare the changes of the immunogenicity measured by wild type SARS-CoV-2 neutralisation test (VNA) against Omicron at Baseline and Days 14, 98 and 182 in subjects of both arms. Wild type neutralisation assay will be performed only in a subset of approximately 20% of the total subjects included in the study.
    4. To evaluate the immunogenicity measured by means of total antibody against RBD of the Spike protein of SARS-CoV-2 quantification, measured by an electrochemiluminescence immunoassay (ECLIA) at Baseline and at Days 14, 98 and 182 in subjects of both arms.
    1. Determinar y comparar los cambios en la immunogenicidad medida mediante PBNA contra VOCs beta y delta, en la visita basal y en los días 14, 98 y 182 en sujetos de los dos brazos.
    2. Determinar y comparar los cambios en la immunogenicidad medidos mediante neutralización por pseudovirión contra Omicron en los días 98 y 182 en sujetosde los dos brazos.
    3. Determinar y comparar los cambios en la immunogenicidad medidos mediante neutralización por virus salvaje (VNA) contra Omicon en la visita basal y en los días 14, 98 y 182 en los sujetos de los dos brazos. El ensayo de neutralización en virus vivo solo se realizará aproximadamente en un 20% de los sujetos incluidos en el estudio.
    4. Evaluar la immunogenicidad medida por la quantificación total de anticuerpos contra Receptor Binding Domain (RBD) de la proteína Spike de SARS-COV-2, medido por immunonesayo de electroquimioluminiscencia (ECLIA) en la visita basal y en los días 14, 98 y 182 en sujetos de los dos brazos.
    .
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Subjects must meet all the following criteria to be considered eligible for the study:
    1. Male or female, ≥ 18 years old at Day 0.
    2. Participant must provide consent indicating that she or he understands the purpose and potential risks and is willing and able to participate in the study and comply with all the study requirements and procedures (scheduled visits, laboratory tests, complete diaries, etc).
    3. Participant who has been vaccinated with two doses of Vaxzevria at least 91 days before Day 0 and a maximum of 365 days of the second dose.
    4. Has a negative Rapid Antigen Test (RAT) at Day 0
    5. Participants may have underlying illnesses if are stable and well-controlled according to the investigator judgment. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months prior to screening and for which neither a significant change in treatment or hospitalization for worsening is expected in the near future.
    6. Participant agrees not to donate blood, blood products and bone marrow at least 12 weeks before and after vaccination.
    7. Contraceptive use should be consistent with local regulation for participants in clinical trials. A. Female participants of childbearing potential [defined as any female who has experienced menarche and until becoming postmenopausal* (defined as having ≥ 12 months amenorrhea prior to screening without an alternative cause) unless is surgically sterile]:
    i. Have a negative pregnancy test on the day of vaccination.
    ii. Use of any acceptable contraceptive method that should be started at screening and until 8 weeks after vaccination except hormonal contraception. Acceptable contraceptive methods are: 1) Hormonal contraception (progestogen-only or combined): oral, injectable or transdermal (patch) at least 30 days before Day 0 and until 8 weeks after vaccination. 2) Intrauterine device. 3)Vasectomized partner (the vasectomized partner should be the sole partner for that participant). 4) Sexual abstinence **, as a form of contraception, is acceptable if in line with the participant’s lifestyle. 5)Condom
    B. Male participants:
    i. Vasectomized participants.
    ii. Refrain from donating sperm for at least 28 days after day 0.
    iii. Agree to use a male condom may be considered in women of childbearing potential partners, from screening and for at least 28 days after day 0.
    iv. Sexual abstinence**, as a form of contraception, is acceptable if in line with the participant’s lifestyle.
    Los voluntarios deben cumplir todos los siguientes criterios para ser elegibles para el ensayo:
    1. Hombre o mujer ≥ 18 años a día 0.
    2. Dispuesto a dar el consentimiento informado indicando que entiende el objetivo del estudio y los riesgos potenciales, y es capaz de participar en el estudio y cumplir con los requisitos y procedimientos del estudio.
    3. Tener una pauta de vacunación con dos dosis de Vaxzevria como mínimo 91 días y como máximo 365 días antes del día 0.
    4. Tienes un test rápido de antígenos negativo a día 0.
    5. Los participantes pueden tener alguna patología o enfermedad si está estable y bien controlada, según criterio del investigador. Una patología se considera estable si no ha requerido cambios significativos en la medicación o hospitalización por empeoramiento de la enfermedad en los 3 meses previos a la visita de preselección y no se prevén cambios significativos en la medicación o hospitalización por empeoramiento de la enfermedad en un futuro próximo.
    6. Aceptar no dar sangre, productos derivados de la sangre, o médula ósea como mínimo 3 meses antes y después de la vacunación.
    7. Tiene que seguir los métodos anticonceptivos para la participación en ensayos clínicos aceptados por las autoridades reguladoras locales.
    A) Las mujeres con capacidad reproductiva: Deben tener un test de embarazo en orina negativo el día 0 antes de la vacunación. Deben usar un método anticonceptivo como mínimo desde la visita de selección hasta 8 semanas después de la vacunación excepto en el caso de los anticonceptivos hormonales.
    Los métodos anticonceptivos aceptados son: anticonceptivos hormonales (iniciados almenos 30 días antes del Día 0 y hasta almenos 8 semanas después de la vacunación.), dispositivo intrauterino, pareja vasectomizada (si es la única pareja sexual), abstinencia sexual, o condón.
    B) Los hombres deben usar un método anticonceptivo aceptado, y debe empezar el uso del día 0 y debe durar hasta 8 semanas después de la vacunación (participantes vasectomizados, condón o abstinencia sexual). / Los hombres deben abstenerse de donar esperma como mínimo hasta 28 días después de la vacunación.
    E.4Principal exclusion criteria
    - History of anaphylactic shock of any kind.
    - History of COVID-19 infection.
    - Participant received or plans to receive live attenuated vaccines within 4 weeks before and after day 0; or other not live vaccines within 14 days before and after day 0.
    - Pregnancy or breast-feeding at screening or Day 0 (vaccination time-point) or willingness/intention to become pregnant during the study.
    - Participant has a clinically significant acute illness (this does not include minor self-limited illness such as mild diarrhoea) or fever (temperature ≥38º C (100.4ºF) at screening or within 48 hours prior to the planned vaccination (Day 0).
    - Participant had a surgery requiring hospitalization (defined as inpatient stay for > 24 hours) before vaccination and he/she has not received the hospital discharge at day 0; or has a surgery requiring hospitalization planned within 12 weeks after study vaccine administration. Minor surgical procedures not requiring hospitalization are accepted.
    - Participant has any active malignancy even if under treatment except for (at the discretion of the investigator): Non-melanoma adequately treated skin cancer without evidence of disease, or, adequately treated uterine cervical carcinoma in situ without evidence of disease, or, adequately treated anal carcinoma in situ without evidence of disease, or, localized prostate cancer.
    - Participant has ongoing severe and non-stable psychiatric condition likely to affect participation in the study (e.g., ongoing and non-stable severe depression, recent suicidal ideation, severe eating disorder, psychosis).
    - Participant has a problematic or risk use of substances including alcohol (except tobacco) that can compromise the study follow-up. Problematic or risk use of psychoactive substances is understood as the one that causes evident damage, whether it is dependence or any other physical, psychological, or social problem or that carries a high risk of suffering these damages. The negative consequences that consumption causes to third parties could be included.
    - Participant has a bleeding disorder (e.g., factor deficiency, platelet disorder), blood dyscrasia, or continuous use of anticoagulants or has any condition that in the opinion of the investigator contraindicates intramuscular injections or frequent phlebotomy. The use of ≤ 325mg of aspirin or ≤ 75mg of clopidogrel per day as prophylaxis is permitted but not combined.
    - Participant has abnormal function of the immune system as in autoimmune diseases, asplenia, recurrent infections or congenital/acquired immunodeficiency. Participants under immune-modifying treatment for any cause. Permitted: participants with stable clinical conditions (e.g., autoimmune thyroiditis, celiac disease, type 1- diabetes) and participants living with HIV with CD4 T cell count ≥ 400 cells/mm3 under stable antiretroviral treatment with a fully suppressed viral load ≥ 1 year are permitted [one or two non-consecutives blips (HIV viral load ≤ 500 viral copies)].
    - Participants have clinically significant and unstable cardiovascular, respiratory, hepatic, neurological, gastrointestinal, renal, or any other medical disorder as judged by the investigator and defined as disease requiring hospitalization or addition of new treatments or major dose adjustments within 3 months before screening.
    - Chronic or recurrent administration (during at least 14 days) of systemic immunosuppressant medication (defined as given by oral or parenteral routes) within 12 weeks preceding the planned administration of study vaccine (Day 0). The use of an oral prednisone dose <10mg per day or equivalent, ocular, topical, inhaled and nasal corticoids are allowed.
    - Subject has received immunoglobulins and/or blood-derived products 12 weeks prior vaccination (Day 0) or expects to receive them during the study.
    Participant received any immunotherapy (monoclonal antibodies, plasma) aimed to prevent or treat COVID-19 within 90 days preceding the planned administration of study vaccine. Monoclonal antibodies for other indications are allowed.
    - Participation in any research involving an investigational product (drug, biologic, device) within 12 weeks prior to vaccination and during the study.
    Participant has donated ≥ 450ml of blood products within 12 weeks before screening.
    Participant has any medical condition and/or finding that in the investigator opinion might increase participant risks, interfere with the study or impair interpretation of study data.
    - Historia de choque anafiláctico de cualquier tipo
    - Historia de infección por COVID-19
    - El participante ha recibido o planea recibir vacuna/s vivas atenuadas 4 semanas antes y después del día 0; u otras vacunas no vivas 14 días antes y después del día 0.
    - Embarazada o dando pecho a día 0, o esperar quedar embarazada durante el estudio.
    - El participante tiene una patología aguda clínicamente significativa o fiebre ( ≥38º C (100.4ºF)) en el screening o 48 horas antes del día 0.
    - El participante ha tenido una cirugía que ha requerido hospitalización antes de la vacunación y aún no ha recibido el alta médica a día 0; o tiene una cirugía planeada que requiera hospitalización en las 12 semanas posteriores a la administración de la vacuna.
    - El participante tiene algún episodio de malignidad aunque esté en tratamiento, excepto el cancer de piel no-melanómico, carcinoma cervical uterino, carcinoma anal, cancer de prostata localizado.
    - El participante tiene una patología psiquiátrica severa y no estable que puede afectar la participación en el estudio.
    - El participante tiene un uso arriesgado o problemático de sustancias incluyendo el alcohol que puede comprometer el seguimiento del estudio.
    - El participante tiene un desorden del sangrado, o tiene alguna condición que a criterio del investigador contraindica la inyección intramuscular.
    - El participante tiene una función anormal del sistema inmune, excepto condiciones estables, como el HIV controlado.
    - El participante tiene una condición cardiovascular, respiratoria, hepática, neurológica, gastrointestinal, renal, o algún otro desorden que no esté estable a juicio del investigador en los 3 meses anteriores al screening o día 0.
    - Administración recurrente o crónica de medicación inmunosupresora.
    - El sujeto ha recibido inmunoglobulinas y/o productos derivados de la sangre 12 semanas antes de la vacunación (día 0) o espera recibirlos durante en estudio.
    - El participante ha recibido algún tipo de inmunoterapia (anticuerpos monoclonales, plasma) para prevenir el COVID-19 en los últimos 90 días antes de día 0. Los anticuerpos monoclonales para otras indicaciones estan permitidos.
    - Participación en alguna investigación que involucre productos en investigación (medicamento, biológico, equipo) en las 12 semanas antes de la vacunación y durante el transcurso del estudio.
    - El participante ha donado ≥ 450ml de sangre o productos derivador 12 semanas antes del screening.
    - El participante tiene alguna condición médica, que a juicio del investigador puede incrementar los riesgos del participante, interferir en el estudio o perjudicar la interpretación de los datos del estudio.
    E.5 End points
    E.5.1Primary end point(s)
    1.1. Neutralisation titre against Omicron strain measured as inhibitory concentration 50 (IC50) by a pseudovirion-based neutralisation assay (PBNA) and reported as reciprocal concentration for each individual sample and geometric mean titre (GMT) for treatment group comparison at Baseline and Day 14
    2.1 Number, percentage, and characteristics of solicited local and systemic reactions through Day 7 after vaccination.
    2.2 Number, percentage, and characteristics of unsolicited local and systemic adverse events (AEs) through Day 28 after vaccination.
    2.3 Number and percentage of serious adverse events (SAEs) through the study duration.
    2.4 Number and percentage of adverse event of special interest (AESI) through the study duration.
    2.5 Number and percentage of medically attended adverse events (MAAE) related to study vaccine through the study duration.
    2.6 Change from Baseline in safety laboratory parameters at Days 14, 98 and 182 after vaccination.
    1.1 Título neutralizante contra la cepa Omicron medido como la concentración inhibitoria 50 (IC50) mediante ensayo de neutralización en pseudovirión y expresado como la concentración recíproca para cada muestra individual y la mediana geométrica del título (GMT) para la comparación de los grupos de tratamiento en la visita basal y el día 14.
    2.1 Número, porcentaje y características de las reacciones locales y las reacciones adversas sistémicas hasta el dia 7 post-vacunación
    2.2 Número, porcentaje y características de los eventos adversos no solicitados y los eventos adverso sistémicos (AEs) hasta el día 28 post-vacunación.
    2.3 Número y porcentaje de los eventos adversos serios (SAEs) durante todo el estudio.
    2.4 Número y porcentaje de los eventos adversos de especial interés (AESI) durante todo el estudio.
    2.5 Número y porcentaje de los eventos adversos médicamente atendidos (MAAE) y relacionados con la vacuna, durante todo el estudio.
    2.6 Cambios en los parámetros de laboratorio en los días 14, 98 y 182 después de la vacunación.
    E.5.1.1Timepoint(s) of evaluation of this end point
    D0, D14, D98, D182
    D0, D14, D98, D182
    E.5.2Secondary end point(s)
    1.1. Neutralisation titre against VOCs (Beta and Delta) measured as IC50 by PBNA and reported as reciprocal concentration for each individual sample and GMT for treatment group comparison at Baseline and Days 14, 98 and 182.
    1.2. Geometric mean fold rise (GMFR) in neutralising antibodies titres against Omicron and VOCs (Beta and Delta) for treatment group comparison at Baseline and Day 14.
    1.3. Neutralisation titre against Omicron measured as IC50 by PBNA and reported as reciprocal concentration for each individual sample and GMT for treatment group comparison at Days 98 and 182.
    1.4. Neutralisation titre measured as inhibitory dilution 50 (ID50) against Omicron by a VNA and reported as reciprocal dilution for each individual sample, and GMT for treatment group comparison at Baseline and Day 14, 98 and 182. This analysis will only be performed in a subset of participants.
    4.1 Binding antibodies titre measured for each individual sample and GMT for treatment group comparison at Baseline and Days 14, 98 and 182.
    4.2 Geometric mean fold rise (GMFR) in binding antibodies titre from Baseline and Days 14.
    4.3 Percentage of subjects that, after a booster dose, have a ≥4-fold change in binding antibodies titre from Baseline and Days 14, 98 and 182.
    1.1 Título neutralizante contra VOCs (Beta y Delta) medidos como el IC50 mediante PBNA y expresado como la concentración recíproca de cada muestra individual, y la GMT para la comparación de los grupos de tratamiento en la visita basal y en los días 14, 98 y 182.
    1.2 Mediana geométrica del fold-rise (GMFR) en los títulos de anticuerpos neutralizantes contra Omicron y las VOCs (Beta y Delta) para la comparación de los grupos de tratamiento en la visita basal y el día 14.
    1.3 Título neutralizante contra Omicron medido como el IC50 mediante PBNA y expresado como la concentración recíproca para cada muestra individual, y la GMT para la comparación entre grupos de tratamiento a día 98 y día 182.
    1.4 Título neutralizante medido como la dilución inhibitoria 50 (ID50) contra omicron mediante VNA y expresado como la dilución recíproca para cada muestra individual, y la GMT para la comparación entre grupos de tratamiento en la visita basal y días 14, 98 y 182. Este análisis solo será realizado en un subset de participantes.
    4.1 El título de anticuerpos de unión para cada muestra individual, y la GMT para la comparación entre grupos de tratamiento en la visita basal y en los días 14, 98 y 182.
    4.2 Mediana geométrica del fold-rise (GMFR) en los títulos de anticuerpos de unión de la visita basal y el día 14.
    4.3 Porcentaje de sujetos que, después de la dosis de refuerzo, tienen un cambio de ≥4 veces en los títulos de anticuerpos des de la visita basal y los días 14, 98 y 182.
    E.5.2.1Timepoint(s) of evaluation of this end point
    D0, D14, D98, D182
    D0, D14, D98, D182
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned5
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    última visita último paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months7
    E.8.9.1In the Member State concerned days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 263
    F.1.3Elderly (>=65 years) No
    F.1.3.1Number of subjects for this age range: 10
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers Yes
    F.3.2Patients No
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state273
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    none
    ninguno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2022-03-10
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2022-03-09
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA